We have been selected as a target company for the second half of 2025 scale-up investment round hosted by the Korea Venture Business Association.

A total of eight companies were selected, and we are hosting investor relations and investment consultation events for investors. Since the second half of last year, venture companies, medical device companies, pharmaceutical companies, and bio companies that require significant funding for new drug development and innovative product development, even without revenue, have been given the opportunity to secure funding through special listings. This was intended to foster successful venture companies. However, due to the significant losses suffered by retail investors who relied solely on announcements from growth companies, the screening and listing requirements have been tightened, completely blocking investment from investors.

Only companies with sales, net income, and operating profit exceeding KRW 10 billion and a sound financial structure are eligible for listing. This makes it difficult to secure early investment, as it is impossible to secure early technology-focused investments without revenue, or to list despite operating losses with a sound financial structure, thereby guaranteeing investor profits. Even promising companies, which have built a solid initial business foundation through global innovation technology development and commercialization, and can scale up and grow with timely investment funds, are losing out on growth opportunities.

The uncertainty surrounding Trump's tariff policy and the technological, quality, and price competitiveness resulting from China's rapid growth are increasingly limiting the ability to pursue fast-follow technologies. Our first-mover digital syringes, which will overcome these challenges and lead the global market, have been highly evaluated for their innovativeness and growth potential. We have been selected for the Venture Association's second-half scale-up rounding. We will do our best to attract investment through IR and investment consultations, fostering a virtuous cycle of growth.

Thank you.